Newer HMG-CoA reductase inhibitor (statin) therapies.
Clin Cardiol
; 24(7 Suppl): II-10-3, 2001.
Article
en En
| MEDLINE
| ID: mdl-11444648
ABSTRACT
Although most patients can achieve their National Cholesterol Education Program goal with a reduction of < or =30% in low-density lipoprotein cholesterol (LDL-C) levels available with all statins, some patients need greater LDL-C lowering. Furthermore, new study data suggest that greater clinical event reduction may be obtained with more aggressive LDL-C lowering and/or with treatment of factors beyond LDL-C. New formulations of statins. including extended-release preparations, are achieving greater reductions in LDL-C levels as well as favorable modification of high-density lipoprotein cholesterol and triglyceride concentrations while maintaining an excellent safety profile.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Inhibidores de Hidroximetilglutaril-CoA Reductasas
/
LDL-Colesterol
Límite:
Humans
Idioma:
En
Revista:
Clin Cardiol
Año:
2001
Tipo del documento:
Article
País de afiliación:
Estados Unidos